Therapeutic Potentials of Phosphodiesterase-5 Inhibitors in Cardiovascular Disease
Authors:
- 30 June 2014
- journal article
- research article
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 15 (2) , 158-167
Abstract
Phosphodiesterase-5 (PDE5) inhibitors have been approved by the US Food and Drug Administration for the treatment of erectile dysfunction and more recently for pulmonary arterial hypertension (World Health Organization functional class I). PDE5 inhibitors can induce vasodilation; in addition, through a complex pathway involving nitric oxide, cyclic guanosine monophosphate, and protein kinase G, it can reduce apoptosis and suppress cell proliferation. The presence of PDE5 inhibitors in various tissues and systemic vasculature make them potential targets in a variety of cardiovascular diseases. In many in vitro and in vivo studies, PDE5 inhibitors have been shown to have positive effects in systolic and diastolic congestive heart failure, ischemic heart disease, doxorubicin cardiomyopathy, and pulmonary arterial hypertension. They also improved vasoconstriction in Raynaud phenomenon, peripheral artery disease, and hypoxic brain conditions. This article reviews the therapeutic potentials of PDE5 inhibitors in different cardiovascular diseases.Keywords
This publication has 56 references indexed in Scilit:
- ACCF/AHA 2009 Expert Consensus Document on Pulmonary HypertensionJACC, 2009
- Effects of 5′-Phosphodiesterase Four-Week Long Inhibition With Sildenafil in Patients With Chronic Heart Failure: A Double-Blind, Placebo-Controlled Clinical TrialJournal of Cardiac Failure, 2008
- Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotectionJournal of Molecular and Cellular Cardiology, 2008
- Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial KATP channels in rabbitsJournal of Molecular and Cellular Cardiology, 2006
- The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: Demonstration of a ceiling effectVascular Pharmacology, 2005
- Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implicationsVascular Pharmacology, 2005
- Effect of Sildenafil on Reperfusion Function, Infarct Size, and Cyclic Nucleotide Levels in the Isolated Rat Heart ModelCardiovascular Drugs and Therapy, 2005
- Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertensionJACC, 2004
- Cellular and molecular pathobiology of pulmonary arterial hypertensionJACC, 2004
- Hypothesis: selective phosphodiesterase-5 inhibition improves outcome in preeclampsiaMedical Hypotheses, 2004